COVID-19 obstetric practice recommendations
COVID-19 obstetric practice recommendations
• Pregnant women should be regularly screened for symptoms consistent
with an upper respiratory infection; any symptom should result in
testing of a naso-pharyngeal swab for COVID-19.
• All women scheduled for induction or caesarean delivery and their support person should be screened for symptoms of COVID-19 24 to 48 hours before arrival at the hospital and re-screened prior to entry to labor and delivery. If the woman screens positive, induction and caesarean should be rescheduled if possible.
• All hospitalized women and their support person should be screened for symptoms daily. If the pregnant woman screens positive for symptoms, she should have a nucleic acid test for COVID-19; and if the support person screens positive, s/he should be sent home. If the nucleic acid tests were sufficiently available, the support person with symptoms of a viral upper respiratory infection would have such testing.
• For pregnant women with COVID-19, Beta-methasone administration should be limited to those at high risk for preterm delivery within 7 days and only given between 23 weeks' and 33 weeks and 6 days' gestation. Women at risk for preterm delivery at 34 weeks to 36 weeks and 6 days should not receive Beta-methasone.
• If cervical ripening is required, outpatient regimens should be prioritised.
• One support person, appropriately masked, should be permitted at the hospital.
• Neuraxial anesthesia is an optimal approach to labor anesthesia. Nitrous oxide should not be used because it might cause aerosolisation of respiratory secretions.
• Labor management and timing of delivery need not be altered during the pandemic. However, pregnant women with moderate or severe COVID-19 that is not improving may experience modest respiratory improvement if they are delivered preterm.
• Healthcare workers who are pregnant should stop face-to-face contact with patients after 36 weeks' gestation.
• All women scheduled for induction or caesarean delivery and their support person should be screened for symptoms of COVID-19 24 to 48 hours before arrival at the hospital and re-screened prior to entry to labor and delivery. If the woman screens positive, induction and caesarean should be rescheduled if possible.
• All hospitalized women and their support person should be screened for symptoms daily. If the pregnant woman screens positive for symptoms, she should have a nucleic acid test for COVID-19; and if the support person screens positive, s/he should be sent home. If the nucleic acid tests were sufficiently available, the support person with symptoms of a viral upper respiratory infection would have such testing.
• For pregnant women with COVID-19, Beta-methasone administration should be limited to those at high risk for preterm delivery within 7 days and only given between 23 weeks' and 33 weeks and 6 days' gestation. Women at risk for preterm delivery at 34 weeks to 36 weeks and 6 days should not receive Beta-methasone.
• One support person, appropriately masked, should be permitted at the hospital.
• Neuraxial anesthesia is an optimal approach to labor anesthesia. Nitrous oxide should not be used because it might cause aerosolisation of respiratory secretions.
• Labor management and timing of delivery need not be altered during the pandemic. However, pregnant women with moderate or severe COVID-19 that is not improving may experience modest respiratory improvement if they are delivered preterm.
• Healthcare workers who are pregnant should stop face-to-face contact with patients after 36 weeks' gestation.
No comments